(Q74551469)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12152028%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

title

DR's orders: human antibody kills tumors by direct signaling (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12152028%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1

Dan L Longo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12152028%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 August 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12152028%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12152028%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12152028%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

781-783

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12152028%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12152028%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nm0802-781

11 November 2019

exact match

0 references

cites work

Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0802-781

7 January 2021

Lymphoma models for B-cell activation and tolerance. II. Growth inhibition by anti-mu of WEHI-231 and the selection and properties of resistant mutants.

1 reference

https://api.crossref.org/works/10.1038%2FNM0802-781

7 January 2021

T-cell tumor elimination as a result of T-cell receptor-mediated activation

1 reference

https://api.crossref.org/works/10.1038%2FNM0802-781

7 January 2021

Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides

1 reference

https://api.crossref.org/works/10.1038%2FNM0802-781

7 January 2021

Phase II Trial of Remitogen™ (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0802-781

7 January 2021

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0802-781

7 January 2021

Identifiers

DOI

10.1038/NM0802-781

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12152028%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference